M1pro Intelligent Blood Collection Robot
The M1pro Intelligent Blood Collection Robot automates venous blood sampling through a combination of dual-modality imaging (infrared and ultrasound), AI-driven vessel analysis, and nine-axis robotic manipulation. Developed by Kairui Medical, the system has demonstrated 95% success rates in preclinical testing and is currently undergoing clinical trials at major hospitals in Sichuan Province.
Product Overview
Blood collection represents one of the most frequent procedures in clinical medicine, with China performing an estimated 16 million venous draws daily. Despite this volume, the procedure remains largely manual, with failure rates reaching 27% for patients without visible veins and higher for challenging populations including neonates, elderly, and obese patients.
The M1pro addresses these challenges through automated vessel identification, path planning, and precision needle insertion. The complete blood draw cycle—from tourniquet application through bandage placement—completes in approximately 90 seconds.
Key Features
Dual-Modality Vessel Imaging The system combines binocular infrared imaging for surface vein mapping with ultrasound scanning for depth and diameter measurement. This fusion approach generates detailed 3D vascular models that enable targeting of vessels as small as 0.5mm diameter.
Nine-Axis Robotic Manipulation A proprietary tri-axial concentric mechanism provides motion error compensation across all joints, achieving operational precision of 0.07mm. The probe tolerance of 0.05mm enables safe puncture of pediatric vessels.
AI Decision Support Machine learning algorithms analyze multimodal sensor data including optical images, ultrasound returns, and force feedback to determine optimal puncture parameters. Real-time trajectory correction during insertion maintains accuracy despite patient movement.
Full Age Coverage Unlike many automated phlebotomy systems that exclude pediatric populations, the M1pro is designed for patients across all age groups from neonates to elderly.
Technical Specifications
Designed for venous blood sampling across all age groups, the M1pro pairs dual-modality imaging with nine-axis robotic control to reach 0.07mm puncture accuracy.
| Parameter | Specification |
|---|---|
| Robotic Axes | 9 axes |
| Puncture Accuracy | 0.07mm |
| Probe Tolerance | 0.05mm |
| Minimum Target Vessel | 0.5mm diameter |
| Imaging Modalities | Infrared + Ultrasound |
| Cycle Time | ~90 seconds |
| Patient Age Range | All ages (including neonates) |
Clinical Applications
Primary Indications
- Routine venous blood sampling
- Pre-operative laboratory workup
- Physical examination blood draws
- Chronic disease monitoring (diabetes, kidney disease)
Target Settings
- Hospital clinical laboratories
- Outpatient blood draw stations
- Physical examination centers
- Community health clinics
Clinical Validation The M1pro has completed nearly 300 clinical cases across three major Sichuan hospitals: West China Hospital, Sichuan Provincial Women’s and Children’s Hospital, and Sichuan Provincial Cancer Hospital.
Regulatory Status
| Region | Status | Notes |
|---|---|---|
| China (NMPA) | Clinical Trials | Class III registration pending; type testing complete |
| Europe (CE) | Planned | CE marking preparation underway |
| USA (FDA) | Not Applied | - |
The company has submitted a National Innovative Medical Device application and initiated the Class III medical device registration process. Approval is anticipated in the near term.
Competitive Positioning
The global automated phlebotomy market includes:
- Vitestro (Netherlands): CE marked August 2024; 95% first-stick success in ADOPT trial
- MagicNurse (China): First globally to obtain Class III NMPA registration for intelligent blood collection
- Kairui Medical M1pro: Positioned as potentially third company worldwide to achieve regulatory approval
Key differentiators for M1pro include full age-range coverage (including neonates), dual-modality imaging fusion, and the proprietary tri-axial concentric precision mechanism.
Frequently Asked Questions
How accurate is the M1pro compared to human phlebotomists?
In animal experiments on rat tail veins (0.44-0.8mm diameter, averaging 0.61mm), the M1pro achieved 95% success rate. This compares favorably to reported human phlebotomist failure rates of 27% for patients without visible veins. Clinical trial data on human subjects is pending publication.
Can the M1pro draw blood from children and infants?
Yes, the system is designed for full age-range coverage including neonates. The 0.07mm precision and 0.05mm probe tolerance enable safe puncture of pediatric vessels as small as 0.5mm diameter.
What is the expected price of the M1pro?
Pricing has not been officially announced. Industry estimates suggest automated blood collection systems may be priced around 600,000 RMB per unit, though actual pricing will depend on configuration and market factors.
How long does a blood draw take with the M1pro?
The complete cycle from patient positioning through bandage application takes approximately 90 seconds, comparable to skilled human phlebotomist performance.
Browse related categories
Sources
Publicly available references used for the data on this page. See data methodology for verification standards.